구조모아 (StructureMoa)항암 chemical structure spider web
방문Clovis OncologyInc.
MPDL3280A(Clovis Oncology, Inc.)은 Non-small Cell Lung Cancer 표적 치료제로, Non-small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: against the PD-L1/PD-1 pathway, both drugs have similar toxicity profiles related to immune-mediated adverse reactions that can generally be monitored and managed with oral cortico. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: ORR 15.4% (ClinicalTrials.gov NCT04665843). 차별점: novel immunotherapy agents like PD-1 checkpoint inhibitors (anti-PD-1 and anti- PDL-1 antibodies) that improve the capacity o.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Active
2026-09-02
Data Confidence · Low
Development Signal · Emerging
Bispecific antibodies targeting PD-1/PD-L1/VEGF in combination with ch
humanized programmed death-ligand 1 (PD-L1) antibody, in renal cell carcinoma (RCC)
novel immunotherapy agents like PD-1 checkpoint inhibitors (anti-PD-1 and anti- PDL-1 antibodies) that improve the capacity o
against the PD-L1/PD-1 pathway, both drugs have similar toxicity profiles related to immune-mediated adverse reactions that can generally be monitored and managed with oral corticosteroids
immune-mediated adverse events occurred in 17% and 4% of patients, respectively, and there were no grade 4 or 5 events
payload accumulation and cell-cycle progression and reward modalities that recruit catalytic, cell-cycle-independent cytotoxic
PD-1 inhibitors had a high
resistance to immunotherapy, primarily due to its low immunogenicity and immune-cold tumor microenvironment
구조화 데이터
Pdx-1-Cre (KPC) mouse
monkeys, mouse, mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Clovis OncologyInc.
MPDL3280A(Clovis Oncology, Inc.)은 Non-small Cell Lung Cancer 표적 치료제로, Non-small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: against the PD-L1/PD-1 pathway, both drugs have similar toxicity profiles related to immune-mediated adverse reactions that can generally be monitored and managed with oral cortico. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: ORR 15.4% (ClinicalTrials.gov NCT04665843). 차별점: novel immunotherapy agents like PD-1 checkpoint inhibitors (anti-PD-1 and anti- PDL-1 antibodies) that improve the capacity o.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Active
2026-09-02
Data Confidence · Low
Development Signal · Emerging
Bispecific antibodies targeting PD-1/PD-L1/VEGF in combination with ch
humanized programmed death-ligand 1 (PD-L1) antibody, in renal cell carcinoma (RCC)
novel immunotherapy agents like PD-1 checkpoint inhibitors (anti-PD-1 and anti- PDL-1 antibodies) that improve the capacity o
against the PD-L1/PD-1 pathway, both drugs have similar toxicity profiles related to immune-mediated adverse reactions that can generally be monitored and managed with oral corticosteroids
immune-mediated adverse events occurred in 17% and 4% of patients, respectively, and there were no grade 4 or 5 events
payload accumulation and cell-cycle progression and reward modalities that recruit catalytic, cell-cycle-independent cytotoxic
PD-1 inhibitors had a high
resistance to immunotherapy, primarily due to its low immunogenicity and immune-cold tumor microenvironment
구조화 데이터
Pdx-1-Cre (KPC) mouse
monkeys, mouse, mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.